Geron Corporation (GERN) Q1 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Hello and welcome to the GERON first quarter 2025 earnings call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question and answer session. If you would like to ask a question during this time, please press star 1 on your telephone keypad. I would now like to turn the conference over to Ron Moldaver, Investor Relations. You may begin. Good morning, everyone. Welcome to the Jaron Corporation first quarter 2025 earnings conference call. Before we begin, please note that during the course of this presentation and question and answer session, we will be making forward-looking statements regarding future events, performance, plans, expectations, and other projections, including those related to the launch, commercial opportunity, and therapeutic potential of Ritello, anticipated clinical and commercial events, and related timelines, the sufficiency of Jerron's financial resources and other statements that are not historical facts. Actual events or results could differ materially. Therefore, I refer you to the discussion under the heading Risk Factors in Jerron's most recent periodic report with the SEC, which identifies important factors that could cause actual results to differ materially from those contained in the forward-looking statement and our future updates to those risk factors. Geron undertakes no duty or obligation to update our forward-looking statements. With that, I'll turn the call over to Dawn Burr, Interim President and Chief Executive Officer. Good morning. Thank you, Ron, and thank you all for joining us. I'll begin on slide four. I'm joined today by several members of Geron's management team. Michelle Robertson, our Chief Financial Officer, Jim Ziegler, our Chief Commercial Officer, and...